Intermediate-dose Cytarabine in Combination with Venetoclax
2024-HS-084
Phase 3 small_molecule active
Quick answer
Intermediate-dose Cytarabine in Combination with Venetoclax for Acute Myeloid Leukemia (AML) is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active